No Data
No Data
Strong Week for Supernus Pharmaceuticals (NASDAQ:SUPN) Shareholders Doesn't Alleviate Pain of Five-year Loss
The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term S
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
TD Cowen analyst Stacy Ku maintains $Supernus Pharmaceuticals(SUPN.US)$ with a buy rating, and maintains the target price at $43.According to TipRanks data, the analyst has a success rate of 23.8% and
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $41
Piper Sandler analyst David Amsellem maintains $Supernus Pharmaceuticals(SUPN.US)$ with a buy rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate o
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38
Stifel analyst Annabel Samimy maintains $Supernus Pharmaceuticals(SUPN.US)$ with a hold rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 45.5
Piper Sandler Sticks to Its Buy Rating for Supernus Pharmaceuticals (SUPN)
No Data
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.